- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02360852
IBAT Inhibitor A4250 for Cholestatic Pruritus
An Exploratory, Phase IIa Study to Demonstrate the Safety and Efficacy of A4250 in Patients With Primary Biliary Cirrhosis and Cholestatic Pruritus
Study Overview
Detailed Description
A4250PBCpruritus (EudraCT 2014-004070-42) is an open-label exploratory study.
The primary objective of this study is to assess the safety and tolerability of A4250, 1.5 - 3 mg orally during a four-week treatment period, in patients with PBC and cholestatic pruritus, as determined by the occurrence of treatment-emergent serious adverse events (SAEs).
Other safety objectives of this study include assessment of the safety and tolerability of A4250 during a four-week treatment period, as determined by the occurrence of treatment-emergent adverse events (AEs) and changes in other safety parameters including liver and kidney function tests and vital signs.
Exploratory efficacy objectives of this study are to demonstrate the efficacy of A4250 orally on pruritus variables and on QoL and lysophosphatidic acid formation as well as evaluation of changes in pharmacodynamic parameters of bile acid metabolism such as serum and fecal bile acids, C4 and fibroblast growth factor 19 (FGF19) assessments and assessment of surrogate markers of cholestatic liver disease such as alkaline phosphatase, transaminases and bilirubin.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Göteborg, Sweden
- Sahlgrenska Academy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Major Inclusion Criteria:
- Diagnosis of PBC or PBC-Autoimmune hepatitis overlap as established according to American Association for the Study of Liver Diseases/European Association for the Study of Liver (AASLD/EASL) definitions. Definite or probable PBC diagnosis, as demonstrated by the presence of ≥ 2 of the following 3 diagnostic factors:
- History of elevated alkaline phosphatase (ALP) levels (>1.67 ULN) for at least 6 months prior to Day 1
- Positive antimitochondrial antibodies (AMA) titer or if AMA negative or in low titer (<1:80) PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components (PDC-E2, 2-oxo-glutaric acid dehydrogenase complex)
- Liver biopsy consistent with PBC;
- Ursodeoxycholic acid (UDCA) non-responders defined as >6 months of UDCA and at the time of enrolment a serum ALP >1.67 ULN;
- Laboratory markers of cholestasis identified within 3 months of Visit 1;
- Treatment with cholestyramine at a dose >4g BID or colestipol > 5mg for at least 3 months;
- The patient has a VAS-Itch of at least 30 mm during the day before baseline (Visit 2);
- The patient is a male or non-pregnant female ≥18 years of age and ≤80 years of age with body mass index (BMI) ≥18.5 but <35 kg/m2;
Major Exclusion Criteria:
- Any condition that, in the opinion of the Investigator constitutes a risk for the patient or a contraindication for participation and completion of the study, or could interfere with study objectives, conduct, or evaluations;
- Jaundice of extrahepatic origin;
- The patient has a structural abnormality of the GI tract;
- The patient has a known, active, clinically significant acute or chronic infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti infectives within 4 weeks of treatment start (study day 1) or completion of oral anti-infective treatment within 2 weeks prior to start of screening period;
- The patient has unexplained and clinically significant GI alarm signals (e.g., lower GI bleeding or heme-positive stool, iron-deficiency anaemia, unexplained weight loss) or systemic signs of infection or colitis;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A4250
A4250 once daily
|
A4250 once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
•Safety and Tolerability assessed by the occurrence of treatment-emergent SAEs during the four weeks of treatment with A4250
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety laboratory measurements
Time Frame: 4 weeks
|
Changes in safety laboratory test results (including hematology, clinical chemistry and urinalysis) from baseline to Day 28 of A4250 treatment
|
4 weeks
|
VAS-Itch
Time Frame: 4 weeks
|
Change in VAS-Itch (most severe itch during last 24 hrs) during the fourth treatment week of A4250
|
4 weeks
|
Itching scale
Time Frame: Four weeks
|
Change in PBC40
|
Four weeks
|
Bile acid evaluation
Time Frame: Four weeks
|
Change in serum and fecal bile acids (BAs)
|
Four weeks
|
Liver biochemistry
Time Frame: Four weeks
|
Change in ALP
|
Four weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Hanns-Ulrich Marschall, MD, Sahlgrenska Academy, Institute of Medicine,
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A4250 PBC Pruritus
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biliary Cirrhosis, Primary
-
University Health Network, TorontoUnknown
-
CymaBay Therapeutics, Inc.TerminatedPrimary Biliary Cirrhosis (PBC)Germany, United States, Canada, United Kingdom, Poland
-
Xijing Hospital of Digestive DiseasesUnknownPrimary Biliary CirrhosisChina
-
IpsenActive, not recruitingPrimary Biliary CirrhosisUnited States, France, Spain, Belgium, Germany, Switzerland, Brazil, United Kingdom, Argentina, Canada, Chile, Italy, South Africa, Turkey
-
Instituto Mexicano del Seguro SocialActive, not recruitingPrimary Biliary CirrhosisMexico
-
University of AarhusAarhus University Hospital; Hvidovre University HospitalRecruiting
-
CymaBay Therapeutics, Inc.RecruitingPrimary Biliary CirrhosisUnited States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
-
Target PharmaSolutions, Inc.Active, not recruitingBiliary Cirrhosis, PrimaryUnited States
-
Zydus Therapeutics Inc.CompletedPrimary Biliary CirrhosisUnited States
-
CymaBay Therapeutics, Inc.CompletedPrimary Biliary CirrhosisUnited States, Germany, United Kingdom, Canada
Clinical Trials on A4250
-
AlbireoCompletedPediatric CholestasisUnited Kingdom, Denmark, France, Germany, Sweden
-
AlbireoActive, not recruitingAlagille SyndromeUnited Kingdom, United States, France, Germany, Netherlands, Italy, Belgium, Malaysia, Poland, Turkey
-
AlbireoApproved for marketingProgressive Familial Intrahepatic CholestasisUnited States
-
AlbireoCelerionCompletedHealthy VolunteersUnited States
-
AlbireoActive, not recruitingProgressive Familial Intrahepatic CholestasisUnited States, Spain, Netherlands, United Kingdom, Turkey, Canada, Italy, Germany, France, Israel, Australia, Belgium, Poland, Saudi Arabia, Sweden
-
AlbireoCompletedAlagille SyndromeUnited States, United Kingdom, France, Germany, Canada, Netherlands, Italy, Malaysia, Belgium, Israel, New Zealand, Poland, Turkey
-
AlbireoCompletedPrimary Biliary Cirrhosis | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis | Orphan Cholestatic Liver DiseasesUnited Kingdom
-
AlbireoCompletedPFIC1 | PFIC2United States, Spain, Netherlands, United Kingdom, Turkey, Canada, Belgium, Italy, Germany, Saudi Arabia, France, Israel, Australia, Sweden, Poland
-
AlbireoEnrolling by invitationBiliary AtresiaSpain, United States, Netherlands, Malaysia, Canada, Germany, Turkey, Italy, France, Australia, Poland, New Zealand
-
AlbireoCompletedPrimary Biliary Cirrhosis | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis | Orphan Cholestatic Liver Diseases